## Claude Negrier

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3786597/publications.pdf

Version: 2024-02-01

20 1,799 11
papers citations h-index

752698 20 g-index

20 20 all docs citations

20 times ranked 1020 citing authors

#	Article	IF	CITATIONS
1	Emicizumab Prophylaxis in Hemophilia A with Inhibitors. New England Journal of Medicine, 2017, 377, 809-818.	27.0	794
2	Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. New England Journal of Medicine, 2018, 379, 811-822.	27.0	489
3	Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. Blood, 2021, 137, 2231-2242.	1.4	133
4	Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica, 2018, 103, e181-e183.	3.5	78
5	The effect of emicizumab prophylaxis on healthâ€related outcomes in persons with haemophilia A with inhibitors: HAVEN 1 Study. Haemophilia, 2019, 25, 33-44.	2.1	63
6	Safety update on the use of recombinant activated factor VII in approved indications. Blood Reviews, 2015, 29, S34-S41.	5.7	50
7	Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra $\hat{A}^{\otimes}$ (sup ): Proposals from the French network on inherited bleeding disorders (MHEMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GIHP). Haemophilia, 2019, 25, 731-737.	2.1	43
8	Onceâ€weekly prophylaxis with glycoPEGylated recombinant factor VIII (N8â€GP) in severe haemophilia A: Safety and efficacy results from pathfinder 2 (randomized phase III trial). Haemophilia, 2019, 25, 373-381.	2.1	29
9	Emicizumab should be prescribed independent of immune tolerance induction. Blood Advances, 2018, 2, 2783-2786.	5.2	26
10	BAY 94â€9027 prophylaxis is efficacious and well tolerated for up to >5 years with extended dosing intervals: PROTECT VIII extension interim results. Haemophilia, 2019, 25, 1011-1019.	2.1	23
11	The effect of emicizumab prophylaxis on longâ€term, selfâ€reported physical health in persons with haemophilia A without factor VIII inhibitors in the HAVEN 3 and HAVEN 4 studies. Haemophilia, 2021, 27, 854-865.	2.1	21
12	Confirmed longâ€term safety and efficacy of prophylactic treatment with BAY 94–9027 in severe haemophilia A: final results of the PROTECT VIII extension study. Haemophilia, 2021, 27, e347-e356.	2.1	12
13	Identification of new <i>F8</i> deep intronic variations in patients with haemophilia A. Haemophilia, 2020, 26, 847-854.	2.1	9
14	The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors. Haemophilia, 2021, 27, 921-931.	2.1	7
15	Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12) Tj ETQq1	1.0.78431 2.1	.4 rgBT /Ove
16	Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Thrombosis and Haemostasis, 2021, 121, 1079-1086.	3.4	5
17	A novel protocol for accurate and reliable postoperative bolus administration of recombinant factor VIIa using an automated miniâ€pump system. Haemophilia, 2019, 25, 1020-1027.	2.1	3
18	Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors. Hamostaseologie, 2020, 40, 606-620.	1.9	3

#	Article	IF	CITATION
19	Management of intracranial haemorrhage in a newborn with inherited factor VII deficiency with the use of rFVIIa aliquots. Haemophilia, 2021, 27, e487-e490.	2.1	2
20	Report of surgeries, their outcome and the thrombin generation assay in patients with Factor XI deficiency: A retrospective singleâ€entre study. Haemophilia, 2022, 28, 301-307.	2.1	2